Treatment of non-small cell lung cancer

被引：0
|
作者：
Reinmuth, N. [2 ]
Heigener, D. [1 ]
Reck, M. [1 ]
机构：
[1] Krankenhaus Grosshansdorf, Onkol Schwerpunkt, D-22927 Grosshansdorf, Germany
[2] Univ Klinikum Heidelberg, Thoraxklin, Heidelberg, Germany
来源：
INTERNIST | 2011年 / 52卷 / 12期
关键词：
NSCLC; Chemotherapy; Anti-EGFR substances; Biomarkers; Angiogenesis; CLASSIFICATION; CHEMOTHERAPY; THERAPY;
D O I：
10.1007/s00108-011-2925-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Within recent years, the treatment of non-small cell lung cancer has become increasingly heterogeneous and complex. New cytotoxic agents and drugs against molecular targets have been developed. Moreover, new indications for therapy such as maintenance therapy have been explored. In addition, by assessing defined molecular markers, it is possible to identify patients who may likely respond to a given treatment. This approach will continue in the future; thus, it will be possible to characterize patient into subgroups based on molecular, histological, or clinical markers. This review will summarize the current state of the art in the treatment of non-small cell lung cancer.
引用
收藏
页码：1414 / 1421
页数：8
相关论文
共 50 条
  • [1] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    [J]. European Surgery, 2006, 38 (1) : 45 - 53
  • [2] Radiation Treatment of Non-Small Cell Lung Cancer
    Zeng, Jing
    Rengan, Ramesh
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2021, 31 (02) : 95 - 96
  • [3] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
  • [4] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [5] On the pharmacogenetics of non-small cell lung cancer treatment
    Santarpia, Mariacarmela
    Rolfo, Christian
    Peters, G. J.
    Leon, Leticia G.
    Giovannetti, Elisa
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317
  • [6] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    [J]. JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [7] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    [J]. INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
  • [8] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    [J]. REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [9] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [10] Aptamers in Non-Small Cell Lung Cancer Treatment
    Wieleba, Irena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    [J]. MOLECULES, 2020, 25 (14):
12345